Dr. Christopher E. Walsh, MD

Dr. Walsh practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Walsh's NPI, 1588694095, was assigned on July 3, 2006. Dr. Walsh holds New York license 226631.

Dr. Walsh's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Walsh also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Walsh's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Walsh to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Walsh practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Walsh's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Walsh is licensed in New York.

CMS data shows 72 Medicare services from Dr. Walsh across 3 procedure codes in 2024, for 80 Medicare patients. Medicare paid $6,882 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 80 Medicare patients who saw Dr. Walsh in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 4.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Walsh's median patient age at 44, with 42% women.

In 2021, Dr. Walsh wrote 18 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $1,686 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

Dr. Walsh accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 439 general payments to Dr. Walsh from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 66% of the total. Novo Nordisk Inc paid the most, $115,000.